Therapeutic Potential of Cannabinoids in Glaucoma

Area of Science:

• Ophthalmology
• Neuroscience
• Pharmacology

Background:

• Glaucoma is a primary cause of irreversible blindness globally.
• Elevated intraocular pressure (IOP) is the main treatable risk factor, yet disease progression persists in some patients.
• Cannabinoids have demonstrated potential benefits in glaucoma management beyond IOP reduction.

Purpose of the Study:

• To review the existing evidence on the effects and therapeutic potential of cannabinoids in glaucoma.
• To discuss the pharmacological mechanisms of cannabinoids concerning IOP, neuroprotection, and ocular hemodynamics.

Main Methods:

• Literature review of studies on cannabinoids and glaucoma.
• Analysis of pharmacological mechanisms involving cannabinoid receptors (CB1, CB2) and the endocannabinoid system.
• Examination of effects on intraocular pressure, neuroprotection, and ocular blood flow.

Main Results:

• Cannabinoids are known to reduce intraocular pressure (IOP).
• The CB2 receptor exhibits anti-inflammatory, anti-apoptotic, and neuroprotective properties, suggesting its therapeutic relevance.
• Cannabinoids' vasodilatory effects may improve optic nerve head blood flow, potentially offering vasoprotective benefits.

Conclusions:

• Cannabinoids present a promising therapeutic avenue for glaucoma, offering neuroprotection and improved ocular hemodynamics.
• Targeting cannabinoid receptors, particularly CB2, may provide novel strategies for managing glaucoma and preventing vision loss.